TY - JOUR
T1 - Acral lentiginous melanoma
T2 - Who benefits from sentinel lymph node biopsy?
AU - Ito, Takamichi
AU - Wada, Maiko
AU - Nagae, Konosuke
AU - Nakano-Nakamura, Misa
AU - Nakahara, Takeshi
AU - Hagihara, Akihito
AU - Furue, Masutaka
AU - Hiroshi, Uchi
N1 - Funding Information:
Supported in part by grants from the National Cancer Center , Japan, and the Ministry of Education, Culture, Sports, Science, and Technology , and the Ministry of Health, Labor, and Welfare , Japan.
Publisher Copyright:
© 2014 American Academy of Dermatology, Inc.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background There are significant clinicopathological, genetic, and biological differences between acral lentiginous melanoma (ALM) and other types of melanoma. Objective We sought to investigate the use of sentinel lymph node (SLN) biopsy for patients with ALM.Methods This was a retrospective review of 116 patients with primary ALM. Melanoma-specific and disease-free survival were estimated using the Kaplan-Meier method, together with multivariate analyses using the Cox proportional hazards regression model.Results All patients were Japanese (48 male and 68 female). Metastases in SLN were noted in 13 of 84 patients who underwent SLN biopsy. No patients with thin ALM (≤1 mm) and only 2 patients with nonulcerated ALM had tumor-positive SLN. Patients with positive SLN had significantly shorter melanoma-specific survival (5-year survival rate, 37.5% vs 84.3%; P <.0001) and disease-free survival (5-year survival, 37.5% vs 77.9%; P =.0024). Among patients with thick (>1 mm) ALM, the influence of SLN positivity on melanoma-specific survival was increased (5-year survival, 22.7% vs 80.8%; P =.0005).Limitations This was a retrospective study and had a small sample size.Conclusions SLN biopsy should be considered for patients with thick or ulcerated ALM. For patients with thin or nonulcerated ones, it may be of limited importance.
AB - Background There are significant clinicopathological, genetic, and biological differences between acral lentiginous melanoma (ALM) and other types of melanoma. Objective We sought to investigate the use of sentinel lymph node (SLN) biopsy for patients with ALM.Methods This was a retrospective review of 116 patients with primary ALM. Melanoma-specific and disease-free survival were estimated using the Kaplan-Meier method, together with multivariate analyses using the Cox proportional hazards regression model.Results All patients were Japanese (48 male and 68 female). Metastases in SLN were noted in 13 of 84 patients who underwent SLN biopsy. No patients with thin ALM (≤1 mm) and only 2 patients with nonulcerated ALM had tumor-positive SLN. Patients with positive SLN had significantly shorter melanoma-specific survival (5-year survival rate, 37.5% vs 84.3%; P <.0001) and disease-free survival (5-year survival, 37.5% vs 77.9%; P =.0024). Among patients with thick (>1 mm) ALM, the influence of SLN positivity on melanoma-specific survival was increased (5-year survival, 22.7% vs 80.8%; P =.0005).Limitations This was a retrospective study and had a small sample size.Conclusions SLN biopsy should be considered for patients with thick or ulcerated ALM. For patients with thin or nonulcerated ones, it may be of limited importance.
UR - http://www.scopus.com/inward/record.url?scp=84917743578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84917743578&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2014.10.008
DO - 10.1016/j.jaad.2014.10.008
M3 - Article
C2 - 25455840
AN - SCOPUS:84917743578
SN - 0190-9622
VL - 72
SP - 71
EP - 77
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -